Myopia Control Efficacy of Spectacle Lenses With Aspherical Lenslets: Results of a 3-Year Follow-Up Study

XUE LI[1], YINGYING HUANG[1], ZIANG YIN, CHENYAO LIU, SIQI ZHANG, ADELINE YANG, BJÖRN DROBE, HAO CHEN, AND JINHUA BAO

• PURPOSE: To investigate myopia control efficacy in children who continued wearing spectacle lenses with highly aspherical lenslets (HAL) or switched from spectacle lenses with slightly aspherical lenslets (SAL) and single-vision spectacle lenses (SVL) to HAL for 1 year after a 2-year myopia control trial.

• DESIGN: This was a 1-year extension of a randomized clinical trial.

• METHODS: Of 54 children who had worn HAL for 2 years, 52 continued wearing HAL (HAL1 group), and of the 53 and 51 children who had originally worn SAL or SVL, 51 and 48 switched to wearing HAL (HAL2 and HAL3 groups) in year 3, respectively. A new SVL (nSVL) group of 56 children was recruited, matched for age, sex, cycloplegic spherical equivalent refraction (SER), and axial length (AL) of the HAL3 group at extension baseline, and used for a comparison of third-year changes. SER and AL were measured every 6 months in year 3.

• RESULTS: During year 3, the mean (SE) myopia progression in the nSVL group was −0.56 (0.05) diopters (D). Compared with nSVL, the changes in SER were less in HAL1 (−0.38 [0.05] D, $P = .02$), HAL2 (−0.36 [0.06] D, $P = .01$), and HAL3 (−0.33 [0.06] D, $P = .005$). The mean (SE) AL elongation in the nSVL group was 0.28 (0.02) mm. Compared with nSVL, the elongation in AL was less in the HAL1 (0.17 [0.02] mm, $P < .001$), HAL2 (0.18 [0.02] mm, $P < .001$), and HAL3 (0.14 [0.02] mm, $P < .001$) groups. Myopia progression and axial elongation were comparable in all 3 HAL groups (all $P > .05$) in year 3.

• CONCLUSIONS: Myopia control efficacy has remained in children who wore HAL in the previous 2 years. Children who switched from SAL or SVL to HAL in year 3 had slower myopia progression and axial elongation than that in the control group. (Am J Ophthalmol 2023;253: 160–168.
© 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/))

"The Myopia Boom" has been widely noticed in recent decades because of the high incidence and young age of myopia onset.[1–3] Recent research predicted that nearly half of the world's population would be myopic by the year 2050, with 10% high myopia.[4] Patients with high myopia are more susceptible to myopia-associated complications, which may cause substantial visual impairment and large health care costs.[5–7] Therefore, strategies to control myopia progression have gained more attention.[8]

A variety of myopia control interventions, such as orthokeratology,[9] multifocal contact lenses,[10,11] bifocal and progressive addition spectacles,[12,13] spectacle lenses with lenslets,[14,15] and atropine[16,17] have been shown to be effective. However, treatment efficacy has been found to vary over time, and this efficacy change is inconsistent among different treatments.[12,14–16] The 2- to 3-year period of myopia control studies showed that defocus-incorporated multiple segment spectacle lenses had the greatest effect in the first 6 months,[18] bifocal spectacles had the greatest treatment effect in the first year,[18] and the efficacy of orthokeratology lenses decreased over time[19,20]; however, 0.01% atropine appeared more effective in slowing myopia progression in the second year than in the first year.[21,22] Treatment efficacy has been thought to be affected by age, baseline refraction, relevant dose, and compliance.[23–25] It is important for clinicians to have long-term efficacy information on any new myopia intervention.

Recently, spectacle lenses with aspherical lenslets (SAL), which generate myopia control signals prior to the retina, have been introduced in clinics for myopia control in chil-

AJO.com Supplemental Material available at AJO.com.
Accepted for publication March 21, 2023.

National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University (X.L., Y.H., Z.Y., C.L., S.Z., H.C., J.B.), Wenzhou, 325027, China; Wenzhou Medical University–Essilor International Research Center (WEIRC) (X.L., Y.H., A.Y., B.D., J.B.), Wenzhou Medical University, Wenzhou, Zhejiang, China; R&D Asia (A.Y., B.D.), Essilor International, Singapore, Singapore

Inquiries to Corresponding authors: Mailing address: Eye Hospital of Wenzhou Medical University, 270 West Xueyuan Road, Wenzhou, Zhejiang, China, 325027; e-mail: chenhao@mail.eye.ac.cn, baojessie@mail.eye.ac.cn

[1] Xue Li and Yingying Huang are joint first authors.

© 2023 The Author(s). Published by Elsevier Inc.
This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)
0002-9394/$36.00
https://doi.org/10.1016/j.ajo.2023.03.030

dren because of their promising myopia control efficacy.[15,26] The results of a 2-year trial[15] showed that spectacle lenses with highly aspherical lenslets (HAL) and SAL slowed myopia progression and axial length (AL) elongation by 0.80 diopters (D), 0.42 D, 0.35 mm, and 0.18 mm, respectively. Our aims in this study are 1) to determine if myopia control efficacy would be sustained in the third year of HAL wear, 2) to determine if myopia control efficacy is exhibited for myopic children who switched from the original SAL or single-vision spectacle lenses (SVL) wear to HAL correction for 1 year, and 3) to evaluate the long-term myopia efficacy of continued treatment of HAL over 3 years.

METHODS

• **STUDY DESIGN:** Subjects completing the 2-year, double-blind, randomized clinical trial[15] (RCT, ChiCTR1800017683) were invited for an extended third-year non blinded study. The subjects who had worn HAL in the RCT continued to wear HAL in the third year (HAL1 group), and the subjects in the original SAL or SVL groups switched to wearing HAL (HAL2 or HAL3 groups, respectively). A new control group (nSVL group) was recruited to evaluate myopia progression in the third year and was combined with the original SVL group to assess the myopia control efficacy of HAL for all 3 years. The Ethics Committee of the Eye Hospital of Wenzhou Medical University approved this study, and all work was carried out following the tenets of the Declaration of Helsinki. Written informed consent and assent were obtained from the subjects and their parents or guardians after verbal and written explanations of the objectives and possible consequences of the study were provided.

• **STUDY PROCEDURES AND DATA COLLECTION:** The procedures of data measurement followed those in the 2-year RCT.[15] Spherical equivalents of cycloplegic autorefraction (SER) and AL were measured every 6 months. SER was obtained using a KR-800 autorefractor (TOPCON Corp, Tokyo, Japan). AL was measured with an optical low-coherence reflectometry device (Lenstar 900, Haag-Streit AG, Koeniz, Switzerland). For cycloplegia, 2 drops of 1% cyclopentolate were instilled 5 minutes apart, and refraction was performed ≥30 minutes after the last drop. The average values of 10 autorefraction measurements and 5 AL measurements were used for data analysis.

• **NEW CONTROL GROUP (NSVL GROUP):** A new control group was recruited from the Eye Hospital of Wenzhou Medical University from July to September 2020. The subjects and their parents or guardians were fully informed and explained the clinically available myopia interventions and provision of only SVL in this study. Inclusion criteria for the nSVL group were based on the participants of the HAL3 group at extension baseline, ie, between 10-15 years of age, with SER ranges −1.75 to −6.00 D, and AL ranges of 23.3-27.0 mm. Moreover, nSVL participants had no history of using myopia control. Annual myopia progression and AL changes in the nSVL group were compared with the third-year changes in the HAL1, HAL2, and HAL3 groups.

• **STATISTICAL ANALYSIS:** Statistical analyses were performed using SPSS software (version 25.0; IBM Corp, Chicago, Illinois, USA). Baseline characteristics and the changes in SER and AL are presented as mean (SE) or as numbers (%). Only right-eye data were included in the analysis because of a strong correlation in the change in SER ($r = 0.75$, $P < .001$) and AL ($r = 0.84$, $P < .001$) between the 2 eyes over a 3-year period. Following Kolmogorov-Smirnov tests for distribution, unpaired *t* tests, Mann-Whitney *U* tests, or repeated-measures analysis of variance tests were used as appropriate. $P < .05$ was considered statistically significant in all cases.

For the HAL1, HAL2, and HAL3 groups, myopia progression and AL elongation during years 1, 2, and 3 were calculated and compared by repeated-measures analysis of variance and post hoc pairwise comparisons using the least significant difference test. Myopia progression and AL elongation in the nSVL were compared with the third-year changes in the 3 treatment groups (HAL1, HAL2, and HAL3) by a generalized linear model approach with adjusting confounding covariates, such as age, sex, numbers of myopic parents, and baseline SER or AL. For intergroup comparisons, the least significant difference test (when $P < .05$) was used.

RESULTS

• **STUDY SUBJECTS:** One hundred seventy myopic children with a mean (SE) age of 10.4 (0.1) years, ranging from 8-13 years, were originally recruited for the 2-year RCT. After 2 years, 151 (89%) participants continued the 1-year extension study (Supplemental Table 1). Fifty-six participants were recruited in the nSVL group, and their age, sex, SER, AL, and number of myopic parents matched the extension baseline of the HAL3 group (Supplemental Table 2). In total, 191 children (HAL1, n = 51; HAL2, n = 50; HAL3, n = 42; and nSVL, n = 48) completed the third year of follow-up (Figure 1).

• **CHANGES IN SER DURING THE THIRD YEAR:** The average (SE) myopia progressions in the third year were −0.38 (0.05) D, −0.36 (0.06) D, −0.33 (0.06) D, and −0.56 (0.05) D in the HAL1, HAL2, HAL3, and nSVL groups, respectively (Figure 2, A and Table 1). Compared with the nSVL group, the mean (SE) SER progression was less in the HAL1 (−0.18 [0.08] D, $P = .02$), HAL2 (−0.20 [0.08] D, $P = .01$), and HAL3 (−0.23 [0.08] D, $P = .005$) groups,



FIGURE 1. Flowchart of the study, showing participant numbers over 3 years. HAL: spectacle lenses with highly aspherical lenslets; SAL: spectacle lenses with slightly aspherical lenslets; SVL: single-vision spectacle lenses; nSVL: new single-vision spectacle lenses group as a control; HAL1: children who had worn HAL in the previous 2-year study and continued wearing HAL in the 3rd year; HAL2: children who had worn SAL in the previous 2-year study and had switched to wearing HAL in the 3rd year; HAL3: children who had worn SVL in the previous 2-year study and had switched to wearing HAL in the 3rd year.



FIGURE 2. The 3rd year changes in SER (A) and AL (B) in the HAL1, HAL2, HAL3 and nSVL groups, and changes in SER (C) and AL (D) from baseline to 36 months. The blue and red dotted lines represent the period (24-36 months) during which the previous SAL and SVL groups wore HAL. The green line shows changes in the HAL group, and the rose red line shows changes in the nSVL group. HAL: spectacle lenses with highly aspherical lenslets; SAL: spectacle lenses with slightly aspherical lenslets; SVL: single-vision spectacle lenses; nSVL: new single-vision spectacle lenses group as a control; HAL1: children who had worn HAL in the previous 2-year study and continued wearing HAL in the 3rd year; HAL2: children who had worn SAL in the previous 2-year study and had switched to wearing HAL in the 3rd year; HAL3: children who had worn SVL in the previous 2-year study and had switched to wearing HAL in the 3rd year.

with no difference among the 3 HAL intervention groups (all $P > .05$).

In the generalized linear model analysis, the extension baseline age (95% confidence interval [CI] 0.015-0.104; $P = .008$) was significantly associated with SER progression. Table 2 shows model-adjusted changes in myopia progression in the third year. Compared with the nSVL group, the differences in myopia progression were −0.13 (0.08) D in the HAL1 ($P = .09$), −0.18 (0.08) D in the HAL2 ($P = .02$), and −0.22 (0.08) D in the HAL3 ($P = .005$) groups.

Among all participants who completed the third year of follow-up, no SER progression was in 20% of the HAL1 group, 18% of the HAL2 group, 24% of the HAL3 group, and 6% of the nSVL group. In contrast, the proportion of participants who showed myopia progression of >0.50 D was 46% in the nSVL group, 25% in the HAL1 group, 26% in the HAL2 group, and 26% in the HAL3 group ($\chi^2 = 9.76$, $P = .14$) (Figure 3).

• **CHANGES IN AL DURING THE THIRD YEAR:** The mean (SE) AL elongations in the third year were 0.17 (0.02) mm, 0.18 (0.02) mm, 0.14 (0.02) mm, and 0.28 (0.02) mm in the HAL1, HAL2, HAL3, and nSVL groups, respectively (Figure 2, B and Table 1), with no differences among the 3 HAL intervention groups (all $P > .05$). Compared with the nSVL group, the mean AL elongations were less in the 3 HAL groups, with mean AL differences (SE) of −0.11 (0.03) mm (HAL1, $P < .001$), 0.10 (0.03) mm (HAL2, $P < .001$), and 0.14 (0.03) mm (HAL3, $P < .001$).

TABLE 1. Mean (SE) and 95% confidence interval of the SER and AL from baseline to 36 months in HAL/HAL1, SAL/ HAL2, SVL/HAL3 and nSVL groups.

Time (months)	HAL/HAL1 (n=51)	SAL/ HAL2 (n=50)	SVL/ HAL3 (n=42)	nSVL (n=48)	HAL/HAL1 (n=51)	SAL/ HAL2 (n=50)	SVL/ HAL3 (n=42)	nSVL (n=48)
	SER (D)				Myopia progression (D)			
0	-2.72 (0.15) [-3.00, -2.42]	-2.33 (0.13) [-2.59, -2.06]	-2.35 (0.13) [-2.61, -2.08]	-	-	-	-	-
6	-2.79 (0.14) [-3.08, -2.51]	-2.49 (0.14) [-2.76, -2.21]	-2.70 (0.13) [-2.96, -2.45]	-	-0.08 (0.04) [-0.17, -0.01]	-0.16 (0.04) [-0.24, -0.08]	-0.36 (0.05) [-0.45, -0.26]	-
12	-2.96 (0.14) [-3.24, -2.67]	-2.80 (0.14) [-3.08, -2.52]	-3.17 (0.13) [-3.43, -2.91]	-	-0.25 (0.06) [-0.36, -0.13]	-0.48 (0.06) [-0.59, -0.36]	-0.82 (0.07) [-0.97, -0.68]	-
18	-3.14 (0.16) [-3.45, -2.82]	-3.05 (0.14) [-3.33, -2.76]	-3.53 (0.14) [-3.81, -3.25]	-	-0.42 (0.08) [-0.58, -0.26]	-0.72 (0.06) [-0.85, -0.59]	-1.16 (0.09) [-1.34, -0.99]	-
24	-3.32 (0.16) [-3.63, -3.01]	-3.35 (0.15) [-3.64, -3.05]	-3.84 (0.14) [-4.11, -3.56]	-3.73 (0.14) [-4.02, -3.44]	-0.61 (0.08) [-0.77, -0.44]	-1.02 (0.07) [-1.16, -0.89]	-1.49 (0.09) [-1.67, -1.31]	-
30	-3.50 (0.16) [-3.82, -3.17]	-3.55 (0.15) [-3.85, -3.26]	-3.99 (0.15) [-4.29, -3.68]	-4.01 (0.15) [-4.30, -3.71]	-0.78 (0.10) [-0.98, -0.58]	-1.23 (0.08) [-1.39, -1.06]	-1.64 (0.11) [-1.86, -1.42]	-0.28 (0.04) [-0.35, -0.20]
36	-3.70 (0.16) [-4.03, -3.37]	-3.71 (0.16) [-4.04, -3.38]	-4.17 (0.15) [-4.48, -3.86]	-4.29 (0.15) [-4.58, -3.99]	-0.99 (0.11) [-1.20, -0.77]	-1.39 (0.10) [-1.58, -1.19]	-1.82 (0.11) [-2.05, -1.59]	-0.56 (0.05) [-0.67, -0.45]
Time (months)	AL (mm)				AL elongation (mm)			
0	24.78 (0.10) [24.59, 24.97]	24.41 (0.11) [24.20, 24.63]	24.68 (0.10) [24.47, 24.89]	-	-	-	-	-
6	24.85 (0.10) [24.65, 25.05]	24.55 (0.11) [24.33, 24.77]	24.88 (0.10) [24.69, 25.09]	-	0.07 (0.01) [0.04, 0.10]	0.14 (0.01) [0.11, 0.16]	0.21 (0.01) [0.18, 0.23]	-
12	24.90 (0.10) [24.69, 25.10]	24.66 (0.11) [24.44, 24.87]	25.04 (0.10) [24.84, 25.23]	-	0.12(0.02) [0.08, 0.16]	0.24 (0.02) [0.20, 0.28]	0.36 (0.03) [0.31, 0.41]	-
18	25.02 (0.11) [24.81, 25.23]	24.81 (0.11) [24.59, 25.03]	25.28 (0.10) [25.08, 25.47]	-	0.24 (0.03) [0.18, 0.30]	0.39 (0.03) [0.34, 0.45]	0.59 (0.03) [0.52, 0.66]	-
24	25.10 (0.11) [24.88, 25.32]	24.92 (0.11) [24.69, 25.14]	25.38 (0.10) [25.18, 25.58]	25.47 (0.12) [25.24, 25.71]	0.32 (0.03) [0.25, 0.39]	0.50 (0.03) [0.44, 0.57]	0.70 (0.04) [0.63, 0.78]	-
30	25.20 (0.11) [24.98, 25.42]	25.02 (0.11) [24.80, 25.25]	25.46 (0.10) [25.26, 25.65]	25.64 (0.12) [25.40, 25.87]	0.42 (0.05) [0.34, 0.50]	0.61 (0.04) [0.53, 0.69]	0.78 (0.04) [0.70, 0.86]	0.16 (0.01) [0.14, 0.18]
36	25.27 (0.11) [25.05, 25.50]	25.10 (0.11) [24.87, 25.33]	25.52 (0.10) [25.32, 25.72]	25.75 (0.12) [25.52, 25.99]	0.49 (0.05) [0.40, 0.58]	0.69 (0.05) [0.59, 0.78]	0.84 (0.05) [0.75, 0.94]	0.28 (0.02) [0.25, 0.31]

AL, axial length; SER, spherical equivalent refraction; HAL: spectacle lenses with highly aspherical lenslets; SAL: spectacle lenses with slightly aspherical lenslets; SVL: single-vision spectacle lenses; nSVL: new single-vision spectacle lenses group as a control; HAL1: children who had worn HAL in the previous 2-year study and continued wearing HAL in the 3rd year; HAL2: children who had worn SAL in the previous 2-year study and had switched to wearing HAL in the 3rd year; HAL3: children who had worn SVL in the previous 2-year study and had switched to wearing HAL in the 3rd year.

TABLE 2. Adjusted changes in SER and AL (mean [SE], 95%CI) in the 3rd year in HAL1, HAL2, HAL3 and nSVL groups.

Time	HAL1 (n=51)	HAL2 (n=50)	HAL3 (n=42)	nSVL (n=48)	Overall P values	Comparisons P values (4 vs. 1; 4 vs. 2; 4 vs. 3; 3 vs. 1; 3 vs. 2; 2 vs. 1)[#]
Myopia progression (D)[a]	-0.41 (0.05) [-0.51, -0.30]	-0.35 (0.05) [-0.46, -0.25]	-0.32 (0.06) [-0.43, -0.21]	-0.54 (0.05) [-0.64, -0.43]	0.03[a]	0.09; 0.02; 0.005; 0.27; 0.66; 0.48
AL elongation (mm)[a]	0.19 (0.02) [0.15, 0.22]	0.18 (0.02) [0.15, 0.22]	0.14 (0.02) [0.10, 0.18]	0.27 (0.02) [0.23, 0.31]	<0.001[a]	0.001; <0.001; <0.001: 0.06; 0.11; 0.79

[a]Values were generated by a generalized linear model approach adjusted sex, age, number of myopic parents, SER and AL at 24 months, with LSD test applied for pairwise comparisons.

[#]1: HAL1; 2: HAL2; 3: HAL3; 4: nSVL.



FIGURE 3. Distribution of changes in SER (left panel) and AL (right panel) among treatment groups during the one-year extension follow-up (the 3rd year). The dash lines and arrows pointed to greater myopia progression and AL elongation. (AL, axial length; SER, spherical equivalent refraction; HAL1: children who had worn HAL in the previous 2-year study and continued wearing HAL in the 3rd year; HAL2: children who had worn SAL in the previous 2-year study and had switched to wearing HAL in the 3rd year; HAL3: children who had worn SVL in the previous 2-year study and had switched to wearing HAL in the 3rd year.)

In the generalized linear model analysis, extension baseline age (95% CI −0.047 to −0.017; $P < .001$) was significantly associated with AL elongation. Table 2 shows model-adjusted mean (SE) AL changes in the third year. Compared with the nSVL group, the differences in AL elongation were 0.08 (0.03) mm in the HAL1 ($P = .001$), 0.09 (0.03) mm in the HAL2 ($P < .001$), and 0.13 (0.03) in the HAL3 ($P < .001$) groups.

AL elongations ≤0.10 mm were 6% in participants in the nSVL group but were 29% in the HAL1 group, 24% in the HAL2 group, and 43% in the HAL3 group. In contrast, the proportion of AL elongations ≥0.3 mm was 40% in the nSVL group, 16% in the HAL1 group, 18% in the HAL2 group, and 24% in the HAL3 group ($\chi^2 = 22.82$, $P = .001$) (Figure 3).

• **CHANGES IN SER AND AL OVER 3 YEARS IN EACH INTERVENTION GROUP:** In the HAL/HAL1 group, the mean changes in SER and AL were −0.99 (0.11) D and 0.49 (0.05) mm over 3 years (Table 1). The annual rate of myopia progression was similar in each of the 3 years for the HAL group ($F_{2,100} = 2.15$, $P = .12$), but the AL elongation changed significantly ($F_{2,100} = 8.21$, $P = .001$). Post hoc analyses indicated that the axial elongation in the third year was significantly faster than that in the first year (mean difference of 0.06 [0.02] mm, $P = .02$) but similar to that in the second year (mean difference of −0.03 [0.02] mm, $P = .13$) (Figure 2, C and D).

In the SAL/HAL2 group, the mean changes in SER and AL in the third year were -0.36 (0.06) D and 0.18 (0.02) mm, respectively. The annual rate of myopia progression was similar in each of the three years. ($F_{2, 98}$=3.01, P=0.05). While the AL elongation in the third year was less than those in the initial first and second years ($F_{2, 98}$=6.89, P=0.002, mean differences [SE] of -0.06 [0.03] mm, -0.08 [0.02] mm; $P = .02$ and $P < .001$).

In the SVL/HAL3group, SER (-0.33 [0.06] D, [$F_{2, 82}$ = 19.33, P < .001]) and AL (0.14 [0.02] mm, [$F_{2, 82}$ = 42.39, P < .001]) changes in the third year were less than those in the first year (mean differences [SE] of 0.49 [0.08] D, -0.22 [0.03] mm; all P < .001) and the second year (mean differences [SE] of 0.33 [0.07] D, 0.19 [0.03] mm; all P < .001).

• **COMPLIANCE AND ADAPTATION:** No significant difference was observed in the proportion of participants who adapted to HAL or SVL within 3 days among the HAL1, HAL2, HAL3, and nSVL groups (100%, 100%, 98% and 100%, respectively; P = .31). Only one participant from the HAL3 group complained of blurred vision, but then adapted well in one week. No adverse events were reported during the extended study period.

DISCUSSION

This study presented the results of a clinical trial extended to 3 years, in which one group wore HAL for 3 years, and the other two groups wore HAL for 1 year after completing the initial 2 years of wearing either SAL or SVL. Over three years, the mean myopia progression and AL elongation were -2.05 D and 0.98 mm in the control group (combined initial SVL and nSVL groups); and -0.99 D and 0.49 mm in the HAL/HAL1 group, resulting in a total difference in myopia progression of 1.06 D (52%) and AL elongation of 0.49 mm (50%).

In the HAL/HAL1 group, myopia progression did not change significantly over 3 years ($F_{2, 100}$ = 2.15, P = .12). However, AL elongation in the second and third years was slightly greater than in the first year (mean difference, 0.09 mm and 0.06 mm, respectively), with no difference between the second and third years. The small change may come from the choroidal thickening caused by HAL in the first year.[27] Moreover, during the second and third years (July 2019 to September 2021), the COVID-19 has spread, resulting in temporary lockdown and more online learning at home, which might have contributed to this minute difference.[28,29]

In the HAL3 group, SER and AL changes in the 3rd year were -0.33 (0.06) D and 0.14 (0.02) mm, significantly less than those in the previous year (-0.67 [0.05] D and 0.34 [0.02] mm), and also less than those in the nSVL group (-0.56 [0.05] D and 0.28 [0.02] mm), indicating that HAL is efficacious in slowing myopia progression and axial elongation in older children (10 to 15 years) wearing HAL for the first time. In contrast, the myopia control efficacy of the switchover group in the LAMP study (from placebo to 0.05% Atropine) showed more dramatic (1st year vs 2nd year, -0.82 D vs -0.18 D; 0.43 mm vs 0.15 mm).[22] We found that the control groups in both studies had inconsistent myopia progression in the year prior to switching (-0.67 D, our study vs -0.82 D, LAMP), possibly due to an over 2-year age difference.[30]

No differences among the 3 HAL treatment groups were found in the 3rd year. This result was similar to previous reports from Chamberlain and associates[31] and Lam and associates.[32] In Chamberlain and associates' study, children from the single-vision contact lens group who switched to wearing dual-focus soft contact lenses (DFCL) for 3 years showed a similar treatment effect to those who continued wearing DFCL. Lam and associates[32] found similar results for children switching to wearing defocus-incorporated multiple segment spectacles for 1 year after SVL. In this study, the myopia control efficacy of HAL was not affected by previous optical correction methods (SVL or SAL). Whether the myopia control efficacy of HAL is affected by previous use of other myopia control treatments, such as low-concentration atropine, needs to be further investigated.

There were some limitations to this study. First, the control group that was used to evaluate the long-term myopia efficacy of HAL over 3 years was formed by combining the initial SVL and new SVL groups. After the 2-year RCT, the initial SVL group switched to wearing HAL lenses. Thus, a new SVL group was recruited as the control group in the third year, and this extension 1-year study was non blinded. However, the myopia progression of average 12 years was comparable to another two studies from mainland China.[33,34] And the predicted AL elongation in year 3 could be 0.289 mm based on a 15% decrease in AL elongation per year by Shamp et al.,[30] which is very comparable with the observed 0.28 mm in the current study. Second, this study was not designed to observe any possible rebound effect as found in atropine studies.[17,35,36] However, a recent cross-over trial has shown that there was no rebound of myopia with HAL, as the rate of progression observed in Vietnamese children (7-11 years) who ceased wearing HAL and switched to SVL was similar to that of the comparative control group wearing SVL.[37]

In conclusion, in Chinese myopic children, wearing HAL effectively slows myopia progression and axial elongation compared with SVL over 3 years. Similarly, when myopic children switched to HAL in the third year after two years of wearing SVL, myopia progression and axial elongation decreased significantly. The myopic children who have been wearing HAL for three years will be followed for two more years to determine the long-term efficacy of HAL lenses over a 5-year period.

Financial Support: This work was supported by the Zhejiang Provincial Leading Health Talent Project (Hao Chen), the Medical and Health Science and Technology Project of Zhejiang Provincial Health Commission of China (grant number 2022PY072), the Basic Scientific Research Project of Wenzhou (grant number Y2020343), and a collaborative research project with Essilor International (Wenzhou Medical University grant numbers 95016010, 95020005).
Role of the Funder/Sponsor: Essilor International participated in the study design, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Conflict of Interest: Adeline Yang and Björn Drobe are employees of Essilor International. This company supplied the study devices. The other authors have no proprietary or commercial interest in any materials discussed in this article.
Abbreviations: AL: Axial length; D: Diopter; OK: Orthokeratology; HAL: Spectacle lenses with highly aspherical lenslets; SAL: Spectacle lenses with slightly aspherical lenslets; SVL: Single-vision spectacle lenses.
Author Contributions: Drs. Bao and Dr. Chen had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Bao, Chen
Acquisition, analysis, or interpretation of data: Li, Huang, Yin, Liu, Zhang.
Drafting of the manuscript: Li
Critical revision of the manuscript for important intellectual content: Li, Huang, Drobe, Chen, Bao.
Statistical analysis: Li, Huang, Yin, Bao.
Obtained funding: Bao, Chen
Administrative, technical, or material support: Bao, Li, Huang, Yang.
Supervision: Bao, Chen.
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. Funding/Support:. Financial Disclosures:. All authors attest that they meet the current ICMJE criteria for authorship.

REFERENCES

1. Dolgin E. The myopia boom. *Nature*. Mar 19 2015;519(7543):276–278. doi:10.1038/519276a.
2. Rudnicka AR, Kapetanakis VV, Wathern AK, et al. Global variations and time trends in the prevalence of childhood myopia, a systematic review and quantitative meta-analysis: implications for aetiology and early prevention. *Br J Ophthalmol*. Jul 2016;100(7):882–890. doi:10.1136/bjophthalmol-2015-307724.
3. Morgan IG, French AN, Ashby RS, et al. The epidemics of myopia: Aetiology and prevention. *Prog Retin Eye Res*. Jan 2018;62:134–149. doi:10.1016/j.preteyeres.2017.09.004.
4. Fricke TR, Jong M, Naidoo KS, et al. Global prevalence of visual impairment associated with myopic macular degeneration and temporal trends from 2000 through 2050: systematic review, meta-analysis and modelling. *Br J Ophthalmol*. Jul 2018;102(7):855–862. doi:10.1136/bjophthalmol-2017-311266.
5. Wong YL, Sabanayagam C, Ding Y, et al. Prevalence, Risk Factors, and Impact of Myopic Macular Degeneration on Visual Impairment and Functioning Among Adults in Singapore. *Invest Ophthalmol Vis Sci*. Sep 4 2018;59(11):4603–4613. doi:10.1167/iovs.18-24032.
6. Fricke TR, Sankaridurg P, Naduvilath T, et al. Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia. *Br J Ophthalmol*. Mar 9 2022. doi:10.1136/bjophthalmol-2021-320318.
7. Foo LL, Lanca C, Wong CW, et al. Cost of Myopia Correction: A Systematic Review. *Frontiers in medicine*. 2021;8:718724. doi:10.3389/fmed.2021.718724.
8. Wildsoet CF, Chia A, Cho P, et al. IMI - Interventions Myopia Institute: Interventions for Controlling Myopia Onset and Progression Report. *Invest Ophthalmol Vis Sci*. Feb 28 2019;60(3):M106–m131. doi:10.1167/iovs.18-25958.
9. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutierrez-Ortega R, Sugimoto K. Long-term Efficacy of Orthokeratology Contact Lens Wear in Controlling the Progression of Childhood Myopia. *Curr Eye Res*. May 2017;42(5):713–720. doi:10.1080/02713683.2016.1221979.
10. Chamberlain P, Peixoto-de-Matos SC, Logan NS, Ngo C, Jones D, Young G. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. *Optom Vis Sci*. Aug 2019;96(8):556–567. doi:10.1097/opx.0000000000001410.
11. Walline JJ, Walker MK, Mutti DO, et al. Effect of High Add Power, Medium Add Power, or Single-Vision Contact Lenses on Myopia Progression in Children: The BLINK Randomized Clinical Trial. *Jama*. Aug 11 2020;324(6):571–580. doi:10.1001/jama.2020.10834.
12. Cheng D, Woo GC, Drobe B, Schmid KL. Effect of bifocal and prismatic bifocal spectacles on myopia progression in children: three-year results of a randomized clinical trial. *JAMA Ophthalmol*. Mar 2014;132(3):258–264. doi:10.1001/jamaophthalmol.2013.7623.
13. Gwiazda J, Hyman L, Hussein M, et al. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. *Invest Ophthalmol Vis Sci*. Apr 2003;44(4):1492–1500. doi:10.1167/iovs.02-0816.
14. Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. *Br J Ophthalmol*. Mar 2020;104(3):363–368. doi:10.1136/bjophthalmol-2018-313739.
15. Bao J, Huang Y, Li X, et al. Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial. *JAMA Ophthalmol*. Mar 31 2022. doi:10.1001/jamaophthalmol.2022.0401.
16. Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). *Ophthalmology*. Feb 2012;119(2):347–354. doi:10.1016/j.ophtha.2011.07.031.
17. Yam JC, Zhang XJ, Zhang Y, et al. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3

Report. Ophthalmology. Mar 2022;129(3):308–321. doi:10.1016/j.ophtha.2021.10.002.
18. Cheng D, Schmid KL, Woo GC, Drobe B. Randomized trial of effect of bifocal and prismatic bifocal spectacles on myopic progression: two-year results. *Arch Ophthalmol*. Jan 2010;128(1):12–19. doi:10.1001/archophthalmol.2009.332.
19. Pauné J, Morales H, Armengol J, Quevedo L, Faria-Ribeiro M, González-Méijome JM. Myopia Control with a Novel Peripheral Gradient Soft Lens and Orthokeratology: A 2-Year Clinical Trial. *Biomed Res Int*. 2015;2015:507572. doi:10.1155/2015/507572.
20. Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. *Invest Ophthalmol Vis Sci*. Oct 11 2012;53(11):7077–7085. doi:10.1167/iovs.12-10565.
21. Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops. *Ophthalmology*. Feb 2016;123(2):391–399. doi:10.1016/j.ophtha.2015.07.004.
22. Yam JC, Li FF, Zhang X, et al. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report. *Ophthalmology*. Dec 21 2019. doi:10.1016/j.ophtha.2019.12.011.
23. Qi Y, Liu L, Li Y, Zhang F. Factors associated with faster axial elongation after orthokeratology treatment. *BMC Ophthalmol*. Feb 8 2022;22(1):62. doi:10.1186/s12886-022-02294-1.
24. Lam CS, Tang WC, Tse DY, Tang YY, To CH. Defocus Incorporated Soft Contact (DISC) lens slows myopia progression in Hong Kong Chinese schoolchildren: a 2-year randomised clinical trial. *Br J Ophthalmol*. Jan 2014;98(1):40–45. doi:10.1136/bjophthalmol-2013-303914.
25. Loh KL, Lu Q, Tan D, Chia A. Risk factors for progressive myopia in the atropine therapy for myopia study. *Am J Ophthalmol*. May 2015;159(5):945–949. doi:10.1016/j.ajo.2015.01.029.
26. Bao J, Yang A, Huang Y, et al. One-year myopia control efficacy of spectacle lenses with aspherical lenslets. *Br J Ophthalmol*. Apr 2 2021. doi:10.1136/bjophthalmol-2020-318367.
27. Huang Y, Li X, Wu J, et al. Effect of spectacle lenses with aspherical lenslets on choroidal thickness in myopic children: a 2-year randomised clinical trial. *Br J Ophthalmol*. Sep 27 2022. doi:10.1136/bjo-2022-321815.
28. Wang J, Li Y, Musch DC, et al. Progression of Myopia in School-Aged Children After COVID-19 Home Confinement. *JAMA Ophthalmol*. Mar 1 2021;139(3):293–300. doi:10.1001/jamaophthalmol.2020.6239.
29. Choi KY, Chun RKM, Tang WC, To CH, Lam CS, Chan HH. Evaluation of an Optical Defocus Treatment for Myopia Progression Among Schoolchildren During the COVID-19 Pandemic. *JAMA Netw Open*. Jan 4 2022;5(1):e2143781. doi:10.1001/jamanetworkopen.2021.43781.
30. Shamp W, Brennan NA, Bullimore MA, Cheng X, Maynes E. Influence of Age and Race on Axial Elongation in Myopic Children. *Investigative Ophthalmology & Visual Science*. 2022;63(7). 257 – A0111-257 – A0111. https://iovs.arvojournals.org/article.aspx?articleid=2782714 .
31. Chamberlain P, Bradley A, Arumugam B, et al. Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. *Optom Vis Sci*. Mar 1 2022;99(3):204–212. doi:10.1097/opx.0000000000001873.
32. Lam CS, Tang WC, Lee PH, et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. *Br J Ophthalmol*. Mar 17 2021. doi:10.1136/bjophthalmol-2020-317664.
33. Qin Z, Peng T, Zhang Z, et al. Myopia progression and stabilization in school-aged children with single-vision lenses. *Acta Ophthalmol*. Jun 2022;100(4):e950–e956. doi:10.1111/aos.15038.
34. Li SM, Wei S, Atchison DA, et al. Annual Incidences and Progressions of Myopia and High Myopia in Chinese Schoolchildren Based on a 5-Year Cohort Study. *Invest Ophthalmol Vis Sci*. Jan 3 2022;63(1):8. doi:10.1167/iovs.63.1.8.
35. Chia A, Chua WH, Wen L, Fong A, Goon YY, Tan D. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. *Am J Ophthalmol*. Feb 2014;157(2) 451-457.e1. doi:10.1016/j.ajo.2013.09.020.
36. Tong L, Huang XL, Koh AL, Zhang X, Tan DT, Chua WH. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. *Ophthalmology*. Mar 2009;116(3):572–579. doi:10.1016/j.ophtha.2008.10.020.
37. Sankaridurg P, Weng R, Tran H, et al. Spectacle lenses with highly aspherical lenslets for slowing myopia: A randomised, double-blind, cross-over clinical trial. *Am J Ophthalmol*. Nov 5 2022. doi:10.1016/j.ajo.2022.10.021.